CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other, “non-CRC” gastrointestinal (GI) neoplasms accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Educational opportunities relevant to the clinical management of both CRC and non-CRC GI tumors are essential to general oncologist delivery of comprehensive cancer care. The introduction of novel biomarkers, genomic signatures and molecular-targeted systemic agents has led to a rapid paradigm shift in the clinical algorithms for these diseases that presents a challenge to practicing oncologists who must grapple with the presentation of ambiguous data sets and their immediate impact on treatment decisions. To bridge the gap between research and patient care, this CME activity uses the input of cancer experts and community physicians to frame a relevant discussion of recent research advances in GI cancers that can be applied to routine clinical practice. This information will help medical oncologists and hematology-oncology fellows formulate up-to-date clinical management strategies for patients.
  
  LEARNING OBJECTIVES

  • Apply the results of emerging clinical research to the best-practice management of select GI cancers originating within (CRC) and outside of (non-CRC) the colon and rectum.
  • Employ biomarkers and novel genomic signatures in counseling patients with Stage II colon cancer about the long-term risk of disease recurrence.
  • Communicate the benefits and risks of anti-VEGF and anti-EGFR biologic therapy to patients with metastatic CRC.
  • Evaluate the role of potential radiosensitizers in the multimodality management of locally advanced rectal cancer.
  • Use clinical and molecular biomarkers to select optimal local and systemic treatment strategies for patients with gastric or gastroesophageal cancer.
  • Effectively integrate the evidence-based use of chemotherapy and molecular-targeted agents into the individualized management of advanced pancreatic cancer.
  • Communicate the benefits and risks of existing and emerging systemic and targeted treatments for patients with advanced hepatocellular or biliary tract cancer.
  ACCREDITATION STATEMENT
   
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  CME credit is no longer available for this issue
  
  This CME activity contains print and web PowerPoint components. The participant should read the text portion. The text portion of this activity contains edited comments and abbreviated slide set presentations, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
  
  COMMERCIAL SUPPORT
  
  
  This program is supported by educational grants from Genentech BioOncology and Lilly USA LLC.
  
  PHARMACEUTICAL AGENTS DISCUSSED IN THIS PROGRAM
  
  This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Ajani — Consulting Agreements: Abraxis BioScience, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Sanofi-Aventis; Paid Research: ACT Biotech Inc, Bristol-Myers Squibb Company, Genta Inc, ImClone Systems Incorporated, Sanofi-Aventis, Taiho Pharmaceutical Co Ltd. Dr Alberts — had no real or apparent conflicts of interest to disclose. Speakers Bureau: Lilly USA LLC. Dr Benson — Advisory Committee: Amgen Inc, Genomic Health Inc, Lilly USA LLC; Paid Research: Amgen Inc, Genentech BioOncology, Sanofi-Aventis. Dr Hochster — Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, Roche Laboratories Inc, Sanofi-Aventis; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, Roche Laboratories Inc, Sanofi-Aventis; Speakers Bureau: Lilly USA LLC. Dr Ilson — Paid Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech BioOncology, Pfizer Inc, Sanofi-Aventis.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: July 2010
  Expiration date: July 2011